Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Pro Medicus Limited ( (AU:PME) ) is now available.
Pro Medicus Limited announced that it is not affected by the recently announced US tariffs on pharmaceuticals, as the company does not engage in the production or sale of pharmaceutical products. This clarification ensures that Pro Medicus’s operations remain unaffected by these tariffs, maintaining its focus on providing cutting-edge medical imaging solutions without any direct implications from the pharmaceutical industry tariffs.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading healthcare informatics company, providing a comprehensive range of medical imaging software and services to hospitals, imaging centers, and healthcare groups worldwide. Founded in 1983, the company transformed into a global provider of advanced medical imaging solutions with the acquisition of Visage Imaging in 2009. Their Visage 7 suite offers an ultra-fast, clinically rich, and scalable platform deployable in both public and private cloud environments, featuring RIS, PACS, Artificial Intelligence, and e-health solutions.
YTD Price Performance: 20.88%
Average Trading Volume: 179,148
Technical Sentiment Signal: Buy
Current Market Cap: A$31.54B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.